HSP90AB1 and triple-negative breast carcinoma: Another phase 2 study showed that the resorcinol-derived HSP90 inhibitor ganetespib (also called STA9090) has clinical activity in trastuzumab-resistant ERBB2-positive as well as triple-negative breast cancer [10].